Value of CHA2DS2-VASC Score as Predictor of Contrast-Induced Nephropathy in Patients with Non-ST Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Dalia Sobhy Khalil *

Al-Mahalla Cardiac Center, Al-Mahalla Alkobra, Gharbia, Egypt.

Sameh Samir Khalil

Cardiovascular Department, Faculty of Medicine, Tanta University, Egypt.

Mohammed Ahmed Elbarbary

Cardiovascular Department, Faculty of Medicine, Tanta University, Egypt.

Medhat Mohamed Ashmawy

Cardiovascular Department, Faculty of Medicine, Tanta University, Egypt.

*Author to whom correspondence should be addressed.


Background: PCI necessitates the usage of iodinated contrast agent which in some cases is accompanied by CIN and the potential for worse outcomes. The current study aimed to use the CHA2DS2-VASc score with its simple and available components as a predictor of risk of developing CIN in NSTEMI cases who will undergo PCI.

Methods: This single center observational study was conducted on 200 cases diagnosed with NSTEMI who were subjected to primary PCI. The basic level of serum Cr was detected at time of admission followed by monitoring for 48 h, and seven days following the approach to detect the occurrence of CIN. Electrocardiogram (ECG) and transthoracic echocardiography are assessed to all patients.

Results: At cut off ≥2 (area under curve (AUC)=0.649), CHA2DS2-VASc could be used as a predictor for post-PCI CIN with sensitivity and specificity, PPV, NPV and accuracy of 77.6%, 52.3%, 34.5%, 87.8% and 58.5% respectively. There was a statistically significant correlation between occurrence of CIN and all the studied factors (female sex, HTN, DM, anemia, CHF, hemoglobin (HBG), pre-existing renal disease, previous stroke, pre-creatinine, 48hrs and 7 days post-creatinine, pre glomerular filtration rate (GFR) and cha2ds-vasc score and dehydration) with exception of age and vascular disease (p>0.05) being non-significant. Contrast volume, CHA2DS VASC score, metformin use, eGFR after 48h and ACEI /ARB II antagonists ’inhibitor use were significant independent predictors for CIN.

Conclusions: In NSTEMI cases who are subjected to PCI, CHADS2 VASC score ≥ 2 is accompanied by a high risk for CIN and in hospital morbidity and mortality. CHA2DS2-VASC score is considered a useful novel, easy, and reliable method to anticipate CIN in NSTEMI cases undergoing urgent P.

Keywords: CHA2DS2-VASC Score, nephropathy, CIN, NSTEMI, percutaneous coronary intervention

How to Cite

Khalil , D. S., Khalil , S. S., Elbarbary , M. A., & Ashmawy , M. M. (2024). Value of CHA2DS2-VASC Score as Predictor of Contrast-Induced Nephropathy in Patients with Non-ST Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Cardiology and Angiology: An International Journal, 13(1), 42–53.


Download data is not yet available.


Gilutz H, Shindel S, Shoham-Vardi I. Adherence to NSTEMI Guidelines in the emergency department: Regression to reality. Crit Pathw Cardiol. 2019;18:40-6.

Piątek Ł, Wilczek K, Janion-Sadowska A, Gierlotka M, Gąsior M, Sadowski M. Outcomes of a routine invasive strategy in elderly patients with non-ST-segment elevation myocardial infarction from 2005 to 2014: Results from the PL-ACS registry. Coron Artery Dis. 2019;30:326-31.

Manfredonia L, Lanza GA, Crudo F, Lamendola P, Graziani F, Villano A, et al. Diagnostic role of echocardiography in patients admitted to the emergency room with suspect no-ST-segment elevation acute myocardial infarction. Eur Rev Med Pharmacol Sci. 2019;23:826-32.

Sanchis J, Núñez J, Bodí V, Núñez E, García-Alvarez A, Bonanad C, et al. Influence of comorbid conditions on one-year outcomes in non-ST-segment elevation acute coronary syndrome. Mayo Clin Proc. 2011;86:291-6.

Poçi D, Hartford M, Karlsson T, Herlitz J, Edvardsson N, Caidahl K. Role of the CHADS2 score in acute coronary syndromes: Risk of subsequent death or stroke in patients with and without atrial fibrillation. Chest. 2012;141:1431-40.

Chan Y-H, Yiu K-H, Lau K-K, Yiu Y-F, Li S-W, Lam T-H, et al. The CHADS2 and CHA2DS2-VASc scores predict adverse vascular function, Ischemic stroke and cardiovascular death in high-risk patients without atrial fibrillation: Role of incorporating PR prolongation. Atherosclerosis. 2014;237:504-13.

Cetin M, Cakici M, Zencir C, Tasolar H, Baysal E, Balli M, et al. Prediction of coronary artery disease severity using CHADS2 and CHA2DS2-VASc scores and a newly defined CHA2DS2-VASc-HS score. Am J Cardiol. 2014;113:950-6.

Kim KH, Kim W, Hwang SH, Kang WY, Cho SC, Kim W, et al. The CHA2DS2VASc score can be used to stratify the prognosis of acute myocardial infarction patients irrespective of presence of atrial fibrillation. J Cardiol. 2015;65:121-7.

Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119-77.

Rear R, Bell RM, Hausenloy DJ. Contrast-induced nephropathy following angiography and cardiac interventions. Heart. 2016;102:638-48.

Tsai TT, Patel UD, Chang TI, Kennedy KF, Masoudi FA, Matheny ME, et al. Contemporary incidence, Predictors, And outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: Insights from the NCDR Cath-PCI registry. JACC Cardiovasc Interv. 2014;7:1-9.

Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44: 1393-9.

Sgura FA, Bertelli L, Monopoli D, Leuzzi C, Guerri E, Spartà I, et al. Mehran contrast-induced nephropathy risk score predicts short-and long-term clinical outcomes in patients with ST-elevation–myocardial infarction. Circ Cardiovasc Interv. 2010;3: 491-8.

Hubbard BL, Newton CR, Carter PM, Fowler JJ, Schaldenbrand J, Singal B, et al. The inability of B-type natriuretic protein to predict short-term risk of death or myocardial infarction in non-heart-failure patients with marginally increased troponin levels. Ann Emerg Med. 2010;56:472-80.

Taşolar H, Çetin M, Ballı M, Bayramoğlu A, Otlu Y, Türkmen S, et al. CHA2DS2-VASc-HS score in non-ST elevation acute coronary syndrome patients: Assessment of coronary artery disease severity and complexity and comparison to other scoring systems in the prediction of in-hospital major adverse cardiovascular events. Anatol J Cardiol. 2016;16:742-48.

Baydar O, Kilic A. CHA2DS2-VASC Score Predicts Risk of Contrast-Induced Nephropathy in Non-ST Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Interventions. Kidney Dis (Basel). 2019;5:266-71.

Chou RH, Huang PH, Hsu CY, Leu HB, Huang SS, Huang CC, et al. CHADS2 score predicts risk of contrast-induced nephropathy in stable coronary artery disease patients undergoing percutaneous coronary interventions. J Formos Med Assoc. 2016;115:501-9.

He H, Chen XR, Chen YQ, Niu TS, Liao YM. Prevalence and Predictors of Contrast-Induced Nephropathy (CIN) in Patients with ST-Segment Elevation Myocardial Infarction (STEMI) Undergoing Percutaneous Coronary Intervention (PCI): A Meta-Analysis. J Interv Cardiol. 2019: 275.

Ipek G, Onuk T, Karatas MB, Gungor B, Osken A, Keskin M, et al. CHA2DS2-VASc Score is a Predictor of No-Reflow in Patients With ST-Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Intervention. Angiology. 2016;67:840-5.

Sabaghian T, Gheydari ME, Divani F. Evaluation of Curcumin (Turmeric Extract) Effect on Prevention of CIN in Patient Under Elective Coronary Angiography, a Randomized Double Blind Placebocontrolled Clinical Trial. Iran J Kidney Dis. 2020;14:198-205.

Timal RJ, Kooiman J, Sijpkens YWJ, de Vries JPM, Verberk-Jonkers I, Brulez HFH, et al. Effect of No Prehydration vs Sodium Bicarbonate Prehydration Prior to Contrast-EnhancedComputed Tomography in the Prevention of Postcontrast Acute Kidney Injury in Adults With Chronic Kidney Disease: The Kompas Randomized Clinical Trial. JAMA Intern Med. 2020; 180:533-41.

Gupta RK, Bang TJ. Prevention of contrast-induced nephropathy (CIN) in interventional radiology practice. Semin Intervent Radiol. 2010;27:348-59.

Pioli MR, Couto RM, Francisco JA, Antoniassi DQ, Souza CR, Olivio MY, et al. Effectiveness of oral hydration in preventing contrast-induced nephropathy in individuals undergoing elective coronary interventions. Arq Bras Cardiol. 2023;120: 529-40.

Mueller C. Prevention of contrast-induced nephropathy with volume supplementation. Kidney Int Suppl. 2006;2006:16-9.

Iftikhar H, Saleem M, Kaji A. Metformin-associated severe lactic acidosis in the setting of acute kidney injury. Cureus. 2019;11:1-4.

Zeller M, Labalette-Bart M, Julliard J-M, Feldman L, Steg G, Cottin Y, et al. 0116: Metformin and contrast-induced nephropathy in diabetic patients treated with primary percutaneous coronary intervention for ST segment elevation myocardial infarction: A multicentre study. Arch Cardiovasc Dis. 2015;7:2-3.

Li M, Li L, Qin Y, Luo E, Wang D, Qiao Y, et al. Elevated TyG index predicts incidence of contrast-induced nephropathy: A retrospective cohort study in NSTE-ACS patients implanted with DESs. Front Endocrinol. 2022;13:99-110.